Hims & Hers Health (NYSE:HIMS) Stock Rating Lowered by Morgan Stanley

Hims & Hers Health (NYSE:HIMS) was downgraded by Morgan Stanley from an “overweight” rating to an “equal weight” rating in a note issued to investors on Tuesday, Marketbeat Ratings reports. They currently have a $60.00 price objective on the stock, up from their prior price objective of $42.00. Morgan Stanley’s target price would suggest a potential downside of 12.88% from the stock’s previous close.

Other equities research analysts also recently issued reports about the company. Citigroup downgraded Hims & Hers Health from a “neutral” rating to a “sell” rating and raised their target price for the company from $24.00 to $25.00 in a report on Friday, January 10th. TD Cowen reissued a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. BTIG Research began coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Piper Sandler raised their target price on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research note on Monday, January 6th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $28.33.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $68.87 on Tuesday. The business’s 50-day moving average is $33.94 and its two-hundred day moving average is $25.19. The firm has a market capitalization of $15.05 billion, a PE ratio of 156.54 and a beta of 1.35. Hims & Hers Health has a 12 month low of $9.22 and a 12 month high of $72.98.

Insider Buying and Selling at Hims & Hers Health

In other news, COO Melissa Baird sold 67,687 shares of the company’s stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $44.71, for a total transaction of $3,026,285.77. Following the completion of the transaction, the chief operating officer now directly owns 706,872 shares of the company’s stock, valued at approximately $31,604,247.12. This represents a 8.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Dudum sold 33,513 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $33.38, for a total value of $1,118,663.94. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $1,118,296.76. This trade represents a 50.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,052,332 shares of company stock worth $32,620,497 over the last 90 days. Insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Large investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio acquired a new position in shares of Hims & Hers Health during the fourth quarter worth approximately $99,000. Neo Ivy Capital Management raised its stake in Hims & Hers Health by 145.4% during the 4th quarter. Neo Ivy Capital Management now owns 166,734 shares of the company’s stock valued at $4,031,000 after acquiring an additional 98,798 shares in the last quarter. PharVision Advisers LLC acquired a new position in Hims & Hers Health during the 4th quarter worth $234,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Hims & Hers Health by 31.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,156 shares of the company’s stock worth $8,225,000 after acquiring an additional 81,495 shares during the period. Finally, Two Sigma Advisers LP grew its stake in shares of Hims & Hers Health by 839.2% in the fourth quarter. Two Sigma Advisers LP now owns 524,100 shares of the company’s stock worth $12,673,000 after purchasing an additional 468,300 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.